- POSITIVE
Quarterly Revenue Akums Drugs & Pharma Sep-2026 Quarterly Revenue is Rs 421 Cr which is growth of 25.1% YoY.
- POSITIVE
Quarterly Net Profit Akums Drugs & Pharma Sep-2026 Quarterly Net Profit is Rs 33 Cr which is growth of 39.1% YoY.
Akums Drugs & Pharma Live Share Price Today, Share Analysis and Chart
NSE 17 Nov, 2026 10:53 AM (IST)
Akums Drugs & Pharma Stock Price Analysis
Day Price Range-0.8% 1 Day return | 716.5 (LTP) 711.4727.8 LowHigh |
|---|---|
Week Price Range-6.4% 1 Week return | 716.5 (LTP) 711.4779.3 LowHigh |
Month Price Range-2.0% 1 Month return | 716.5 (LTP) 658806.4 LowHigh |
52 Week Price Range68.9% 1 Year return | 716.5 (LTP) 409.3838.8 LowHigh |
Akums Drugs & Pharma Forecaster - Analyst Share Price Target and Estimates
Revenue forecast
EPS forecast
Consensus Recommendation
Akums Drugs & Pharma quarterly results: revenue, profit, and P&L – 13 quarter history
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 420.8 | 418.4 | 366.1 | 398.2 | 336.4 | 361 | 360.8 | 371.3 | 360.5 | 343.5 | 325 | 408 | 469.2 | ||
Operating Exp. | 360.5 | 343.8 | 326.6 | 343.9 | 292.4 | 288.3 | 311 | 303.4 | 285.3 | 273.6 | 358.9 | 351.4 | 357.7 | |
Operating Profit | 34.6 | 48.5 | 11.8 | 24.7 | 16.9 | 44.1 | 17.7 | 34 | 43.1 | 43.7 | -60.5 | 31.7 | 89.3 | |
Operating Profit Margin % | 8.75% | 12.36% | 3.48% | 6.69% | 5.46% | 13.27% | 5.39% | 10.08% | 13.12% | 13.77% | -20.29% | 8.28% | 19.98% | |
Depr. | 13.5 | 12.8 | 12.4 | 12.2 | 10.7 | 10.3 | 10.1 | 10.7 | 9.4 | 9.4 | 9.1 | 8.3 | 7.9 | |
Interest | 3 | 2.5 | 2.6 | 2.5 | 2.1 | 2.9 | 2.6 | 2.3 | 4.2 | 6.2 | 4.8 | 4.8 | 4.5 | |
Profit Before Tax | 43.9 | 59.3 | 21.8 | 35.9 | 31.2 | 59.5 | 37.1 | 54.9 | 61.6 | 54.3 | -49 | 43.5 | 81 | |
Tax | 11.2 | 14.5 | 6.6 | 7.8 | 7.7 | 14.6 | 9.5 | 13.7 | 11.3 | 12.4 | 8.8 | 14.1 | 28.2 | |
Net Profit | 32.6 | 44.8 | 15.2 | 28.1 | 23.5 | 44.9 | 27.6 | 41.2 | 50.4 | 41.9 | -57.9 | 29.3 | 52.8 | |
EPS Adj. latest | 2.1 | 2.9 | 1 | 1.8 | 1.5 | 2.9 | 1.8 | 2.6 | 3.2 | 2.7 | -3.7 | 1.9 | 3.4 | |
Net profit TTM | 120.8 | 111.6 | 111.6 | 124 | 137.1 | 164 | 161 | 75.5 | 63.7 | 66.1 | -165.5 | - | - | |
Basic EPS TTM | 7.9 | 7.3 | 7.3 | 8.1 | 9 | 10.7 | 10.5 | 4.9 | 4.2 | 4.6 | -11.6 | - | - | |
Earnings Transcripts | ||||||||||||||
AI Summary | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
Akums Drugs & Pharma Technical Analysis
Akums Drugs & Pharma EMA & SMA
| 5 Day | 740.6 |
|---|---|
| 10 Day | 742.5 |
| 12 Day | 742.3 |
| 20 Day | 743.3 |
| 26 Day | 744.9 |
|---|---|
| 50 Day | 743.9 |
| 100 Day | 713.6 |
| 200 Day | 655.6 |
Akums Drugs & Pharma Delivery And Volume
Akums Drugs & Pharma Resistance and Support
| First Resistance | 742.7 |
|---|---|
| Second Resistance | 763.1 |
| Third Resistance | 775.8 |
| First Support | 709.5 |
|---|---|
| Second Support | 696.8 |
| Third Support | 676.4 |
| Day RSI | 43.6 |
|---|---|
| Day MACD | -2.6 |
| Day MFI | 69.4 |
| Day MACD Signal Line | -4.3 |
Akums Drugs & Pharma Beta
| 1 Month | 0.6 |
|---|---|
| 1 Year | 0.8 |
| 3 Month | 0.4 |
|---|---|
| 3 Year | - |
Akums Drugs & Pharma Price Change Analysis
Akums Drugs & Pharma Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| RUBY QC INVESTMENT HOLDINGS PTE.LTD. | Block | Sell | 22 Dec 2025 | 428 | 7,278,535 | NSE |
| ICICI PRUDENTIAL MUTUAL FUND | Block | Purchase | 22 Dec 2025 | 428 | 7,278,535 | NSE |
| RUBY QC INVESTMENT HOLDINGS PTE.LTD. | Bulk | Sell | 22 Dec 2025 | 428 | 7,278,535 | NSE |
| ICICI PRUDENTIAL MUTUAL FUND | Bulk | Purchase | 22 Dec 2025 | 428 | 7,278,535 | NSE |
| SMALLCAP WORLD FUND INC | Bulk | Purchase | 06 Aug 2024 | 753.84 | 2,586,541 | NSE |
Akums Drugs & Pharma Corporate Actions
Akums Drugs & Pharma Dividend history and yield
Akums Drugs & Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Akums Drugs & Pharma dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
103 Jul 2026 | 1 | FINAL | 03 Jul 2026 | Equity Share |
203 Jul 2026 | 2 | SPECIAL | 03 Jul 2026 | Equity Share |
Akums Drugs & Pharma Board Meetings
Akums Drugs & Pharma past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
102 Nov 2026 | Quarterly Results | - |
208 Aug 2026 | Quarterly Results | - |
314 May 2026 | Audited Results & Final Dividend | - |
413 Feb 2026 | Quarterly Results | - |
513 Nov 2025 | Quarterly Results | - |
Akums Drugs & Pharma Research Reports
Akums Drugs & Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 103 Nov 2026 | ICICI Securities Limited Target | 925 | 751.5 | Buy | 23.09% | -4.66% | |
| 210 Aug 2026 | ICICI Securities Limited Target | 850 | 760.95 | Buy | 11.7% | -5.84% | |
| 316 Feb 2026 | ICICI Securities Limited Target | 680 | 489.95 | Buy | 38.79% | 46.24% | |
| 421 Dec 2025 | ICICI Securities Limited Target | 600 | 443.15 | Buy | 35.39% | 61.68% | |
| 514 Nov 2025 | ICICI Securities Limited | 565 | 424.3 | Buy | 33.16% | 68.87% |
Akums Drugs & Pharma Corporate Filings
Akums Drugs & Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 10 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Intimation of Schedule of the Investors/Analysts Meet | |
| 05 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 | |
| 03 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Audio recording of Earning/ Quarterly Conference Call | |
| 03 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Newspaper Publication | Newspaper Publication | |
| 03 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report | Final Report of CRISIL Ratings Limited, Monitoring Agency |
Akums Drugs & Pharma Documents
Akums Drugs & Pharma Earnings Call
Akums Drugs & Pharma earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 05 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | |
| 03 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | |
| 13 Aug 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | |
| 10 Aug 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | |
| 10 Aug 2026 | Akums Drugs & Pharmaceuticals Results Earnings Call for Q1FY27 | AudioVideo |
Akums Drugs & Pharma Annual Reports
Akums Drugs & Pharma financials, including annual results, balance sheets, and cash flow statements.
Akums Drugs & Pharma Credit Ratings
Akums Drugs & Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 09 Apr 2026 | icra ratings | Akums Drugs & Pharmaceuticals Limited | Ratings reaffirmed for bank facilities and assigned for commercial paper programme | Link |
| 08 Apr 2025 | icra ratings | Akums Drugs & Pharmaceuticals Limited | Ratings reaffirmed | Link |
| 30 Jan 2025 | icra ratings | Akums Drugs & Pharmaceuticals Limited | Update on material Event | Link |
| 08 Oct 2024 | icra ratings | Akums Drugs & Pharmaceuticals Limited | Long-term rating upgraded to [ICRA]AA(Stable); short-term rating reaffirmed | Link |
Akums Drugs & Pharma Investor Presentations
Akums Drugs & Pharma investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 02 Nov 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 08 Aug 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 14 May 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 13 Feb 2026 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 13 Nov 2025 | Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation |
Akums Drugs & Pharma - Company Profile
Akums Drugs & Pharma Management Structure
Akums Drugs & Pharma management structure with salaries, total experience, and qualifications.
Akums Drugs & Pharma Board of Directors
Akums Drugs & Pharma Board of directors with salaries, total experience, and qualifications.
About the company - Business Profile
Akums Drugs & Pharmaceuticals Ltd. is a dominant player in the Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. The company provides end-to-end solutions, from formulation development and bio-equivalence studies to manufacturing and regulatory compliance. With a presence in over 70 countries, it serves a large client base, including major domestic and international pharmaceutical companies.
Key Points
Key Facts and Operations
- Founded: Incorporated in April 2004.
- Headquarters: New Delhi, India.
- Listing: The company completed its Initial Public Offering (IPO) in August 2024 and is listed on the NSE and BSE.
- Manufacturing Assets: Operates 14 manufacturing facilities (as of March 2025), including 11 for CDMO and 3 for Active Pharmaceutical Ingredients (API). Major sites are located in Haridwar, Kotdwar, and Baddi.
- Infrastructure: Notable assets include a new injectable facility in Haridwar (commenced 2024) and recent land acquisitions in Jammu for future plant expansion.
- R&D: Operates an R&D lab in Mumbai and holds over 21,000 SKUs across diverse therapeutic segments.
Business Model and Segment Performance Akums operates through a cost-plus business model for its CDMO segment, making its margins sensitive to fluctuations in raw material prices. It excels in delivering high-volume, complex dosage forms like injectable/sterile products, hormonal treatments, and nutraceuticals.
Revenue Breakdown (FY 2024-25) The company reported a total revenue of INR 4,118.20 Crores for the fiscal year ended March 31, 2025.
| Business Segment | Revenue (INR Cr) | EBITDA Margin (%) |
|---|---|---|
| CDMO | 3,209.1* | 13.03% |
| API | 219.0 | -19.52% |
| Branded & Generic Formulations | 690.8* | 14.05% |
\Segment revenue derived from reported segment results and margins in annual data.*
Market and Strategic Significance
- Market Share: While industry volumes in the Indian Pharmaceutical Market (IPM) remained muted (1.2% growth in Q3FY26), Akums achieved double-digit volume growth in the same period.
- Global Reach: Exports are a major focus, with facilities holding accreditations from EU-GMP, ANVISA (Brazil), and NSF (US).
- Operational Trends: API prices fell by 8-10% YoY in 2025, impacting absolute EBITDA due to the cost-plus nature of the CDMO business. However, the company is seeing operating leverage play out as capacity utilization reached 47% by Q3FY26.
Innovation and Future Outlook
- Technology Advancements: The company utilizes proprietary delivery systems such as FAST ABSOL, Spornam Technology, and Entroseal. It is actively expanding into differentiated dosage forms like lyophilized vials, pre-filled syringes, and gummies.
- Sustainability & Strategic Initiatives: Current initiatives include the ramp-up of the new injectable facility in Haridwar (adding vial and LVP FFS lines) and rationalizing the portfolio in the loss-making API and trade generics segments.
- Financial Health: Following the IPO, the debt-equity ratio improved to 0.00 as of March 2025 (from 0.69 in 2024), indicating a significantly de-leveraged balance sheet.
